Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer

Clinical trial NCT06837792 · RECRUITING

Trial details

NCT number: NCT06837792
Sponsor: Yonsei University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)

Start date: 2023-10-01
Primary completion: 2026-10-01
Enrollment: 141

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.